RE: RNS10 Jan 2022 13:50
@Paul0410 you raise some interesting points.
From their previous RNS, a few things were important points a) the number of samples was small and b) they stated that the test was useful for detecting those with "higher loads".
As samples were small it was imperative to test further either clinical samples or in lab to confirm sensitivity was reduced and answer why. This process would take the time frame from Mid December to now and I believe that they wouldn't have access to this information when they released the RNS back in December.
However, there is an important question of strategic direction for AffiDX®. The UK Government has blocked the tests (as evidenced by the recent fiasco). This then opens the question of pursuing the US market and the RoW. As mentioned above, the emphasis by the FDA has been accuracy above everything, they don't import cheap low efficacy products like we do here (i.e. Innova). Once that is taken in context, the direction is taken would require Avacta to (rightly) pause the test whilst they finetune. What is great to see is that Abingdon are fully on board to expedite the process.
With the above being said, it isn't a problem as such with the BoD and I believe that many small investors have over reacted with their comments as they aren't aware of nuances and context. Having said that, this provides a good opportunity to buy.
As I mentioned in another thread:
Trinity Delta released their report [1] today:
"Our prior Avacta valuation was £710m (280p per share), with the Diagnostic opportunities representing £133m."
As the pre|CISION platforms is unaffected by todays announcement, the therapeutics arm is worth £577 million i.e. 171p per share.
1. https://www.trinitydelta.org/wp-content/uploads/2022/01/AVCT-Lighthouse-220110.pdf
GL
Sign In
Follow the stocks
